Dossier assessment
Extract from Cannabis sativa (spasticity due to multiple sclerosis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Report documents
-
Extract of dossier assessment
Extract from Cannabis sativa (spasticity due to multiple sclerosis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
-
Dossier assessment
Extract from Cannabis sativa (spasticity due to multiple sclerosis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Dossier assessment
Adults with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrated improvement in spasticity-related symptoms during an initial trial of therapy
Hint of an added benefit with the extent "non-quantifiable", at most "considerable"
Additional information
Federal Joint Committee (G-BA)
2018-11-01 A G-BA decision was published.
Project details
- Project no.
- A18-27
- Commission
- Commission awarded on 26.04.2018 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Muscles, bones and joints
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Extract from Cannabis sativa L. - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed